Caixin Global – Latest China News & Headlines

Home >

Provincial Party Chief Calls On Xiongan to Become Tech Powerhouse
Shanghai Paves the Road for Autonomous Vehicles
Uber-Like Truck-Rental Startup Mulls IPO After Breaking Even
LATEST to Open More Than 200 In-Carrefour Stores by September
Experts: Huawei’s Offer to License 5G Technologies a ‘Smart PR Move’
Shanghai Paves the Road for Autonomous Vehicles
Provincial Party Chief Calls On Xiongan to Become Tech Powerhouse
What Tepid Reception? Notches Turbocharged iPhone 11 Preorders
China’s Internet Safety Week Begins With Alarming Report on Data Privacy
Opinion: No, China Isn’t Waiting Out Trump for a Better Trade Deal
In Depth: Is China’s Animation Industry Ready to Take Off?
Uber-Like Truck-Rental Startup Mulls IPO After Breaking Even
China Evergrande Plans to Build Electric Cars, Batteries in Qingdao
Terry Gou-Backed LCD Panel Plant Seeks Cash Injection
Self-Driving Taxi Industry to Hit Key Inflection Point Next Year, Insider Says
Video App Kuaishou Mulls U.S. IPO, Raises Funds at $25 Billion Valuation
London Stock Exchange Bid in the Works For Long Time: HKEx Chairwoman
Chinese Investors React Coolly to Signs of Easing Trade Tensions
Kweichow Moutai Toasts Long-Term Partnership With Chinese Genomics Giant
After Opening Gates to Outside Food, Disney Clarifies What Is and Isn’t Allowed
Chinese Scientists Edit DNA in Attempt to Cure Man’s Cancer, HIV
China's Electric-Car Sales Drop for Second Straight Month
Fosun Biotech Unit Henlius Aims to Raise $477 Million in Hong Kong IPO

Fran Wang / Feb 06, 2019 06:47 PM / Business & Tech

Photo: VCG

Photo: VCG

EdiGene Inc., a Beijing-based company developing genome-editing technologies into therapeutics for genetic diseases and cancer, announced it has completed a new round of fund-raising worth $10 million.

The company’s series pre-B plus financing was led by venture capital firm Green Pine Capital Partners, which invests in biotech, new materials, new resources, artificial intelligence and other areas, EdiGene said in a statement earlier this week.

“Our portfolio is entering into an exciting stage, and this new round of financing further validates and continues to support our strategy of translating proprietary platforms into potential therapeutics to patients in need,” said EdiGene CEO Wei Dong.

IDG Capital and Lilly Asia Ventures, which led investment in EdiGene’s series A and series B financing, respectively, are among other investors in this round, according to the statement.

EdiGene was founded in 2015 and currently has subsidiaries in southern China’s Guangzhou and Cambridge in the U.S.

Genome editing has been in the spotlight since late last year, when Chinese scientist He Jiankui said a team he led had removed genes from two fetuses in an attempt to make them HIV-resistant. He said the resulting children were born in November. This led to international condemnation, with the government ordering inspections of gene-editing work at universities nationwide and He himself disappearing from public view.

Related: ‘Pursuit of Fame’ Drove Controversial Gene-Editing Project, Investigation Says

Share this article
Open WeChat and scan the QR code